产品
编 号：F758048
产品类型
规格
价格
是否有货
结构图
CAS No: 400010-39-1
产品详情
生物活性：
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts.
体内研究：
Cantuzumab mertansine (SB-408075; huC242-DM1; 300 μg/kg/天; 持续 5 天) 使携带 COLO 205 结肠癌人异种移植物的小鼠完全消退和治愈。Animal Model:Female CB-17 SCID mice, 6-7 weeks of age bearing COLO 205 human colon tumor xenografts
Dosage:300 μg/kg
Administration:Daily for 5 days
Result:Completely eliminated any measurable tumors within 2 weeks of the initiation of therapy, and all eight animals were tumor-free for 200 days (duration of the experiment).
体外研究：
Cantuzumab mertansine (SB-408075; huC242-DM1; 0-100 μM; 24 小时) 对抗原阳性 COLO 205 细胞系具有选择性细胞毒活性。
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts.
体内研究：
Cantuzumab mertansine (SB-408075; huC242-DM1; 300 μg/kg/天; 持续 5 天) 使携带 COLO 205 结肠癌人异种移植物的小鼠完全消退和治愈。Animal Model:Female CB-17 SCID mice, 6-7 weeks of age bearing COLO 205 human colon tumor xenografts
Dosage:300 μg/kg
Administration:Daily for 5 days
Result:Completely eliminated any measurable tumors within 2 weeks of the initiation of therapy, and all eight animals were tumor-free for 200 days (duration of the experiment).
体外研究：
Cantuzumab mertansine (SB-408075; huC242-DM1; 0-100 μM; 24 小时) 对抗原阳性 COLO 205 细胞系具有选择性细胞毒活性。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备